Breast cancer patients at Blumenthal Cancer Center have access to the most current and innovative research studies available in the United States. High-risk individuals who do not have breast cancer also may participate in national breast cancer prevention studies.

Below are the open protocols available for breast cancer treatment:

• Aventis 3001
  RPR109881 IV Every 3 Weeks vs. Capecitabine Tablets 2x/Day for 2 Weeks in 3 Week Cycles for Metastatic Breast Progressing After Taxanes and Anthracycline Therapy. Phase III.
• CMC DDTNAC
  Neoadjuvant, Stage II & III. Dose Dense Taxotere + Navelbine vs. Taxotere - Ariamycin + Cytoxan - Surgery. Phase II.
• GlaxoSmithKline dHER2 Vaccine
  Dose-Escalation Vaccine of dHER2 Protein with AS15 Adjuvant In HER2-Overexpressing High Risk Patients. Phase I.
• Wyeth 303
  Randomized, Placebo-Controlled, Double Blind Study of Oral CCI-779 + Letrozole + Letrozole Alone as First Line Hormonal Therapy in Postmenopausal Women with Locally Advanced or Metastatic Breast Cancer. Phase III.
• CTSU MA.27
  Exemestane vs. Anastrozole in Postmenopausal Women with Receptor Positive Primary Breast Cancer. Phase III.
• IBCSG 24-02
  Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women w/ Endocrine Responsive Breast Cancer. Phase III.
• NSABP B-35
  DCIS, S/P Lumpectomy, Post Menopausal, RT + Tamoxifen vs. RT + Anastrazole. Phase III.
• NSABP B-36
  Adjuvant Therapy Comparing 6 Cycles of 5-FU, Epirubicin and Cyclophosphamide (FEC) to 4 Cycles of AC in Pts. with Node- Negative Breast Cancer. Phase III.
• NSABP B-38
  Adjuvant Trial Comparing Three Chemotherapy Regimens in Women w/ Node-Positive Breast Cancer: Docetaxel/Doxorubicin/ Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide - DD Paclitaxel; DD AC - DD Paclitaxel + Gemcitabine. Phase III.
• RTOG 98-04
  DCIS - Good Risk. Obs (+/- Tam) vs. RT (+/- Tam). Phase III.
• SWOG S0230
  LHRH Analog Administration During Chemo to Reduce Ovarian Failure Following Standard Adjuvant Chemo in Early Stage, Hormone-Receptor Negative Breast Cancer. Phase III.
• SWOG S0347
  Randomized Study of Wkly Vinorelbine Alone or in Combination with Trastuzumab for Pts. with HER-2 Positive Metastatic Breast Cancer Whose Tumors Have Progressed After Taxane + Trastuzumab Combination Therapy. Phase III.
• NSABP B-37
  Adjuvant Chemo for Radically Resected Loco-Regional Relapse of Breast Cancer. Phase III. (0, 8/05)
• RTOG 0413
  Conventional Whole Breast Irradiation vs. Partial Breast Irradiation for Women with Stage O, I, or II Breast Cancer. Phase II. (0, 7/05)